Official ESCRS | European Society of Cataract & Refractive Surgeons

Long term improvement of hyperopic anisometropic amblyopia using

Session Details

Session Title: Special Cases
Session Date/Time: Friday 20/02/2015 | 08:30-10:30
Paper Time: 09:26
Venue: Sadirvan B
First Author: : M.Diab SAUDI ARABIA
Co Author(s): :    S. Eissa              

Abstract Details


Corneal refractive surgery has been used sparingly in the pediatric population; mostly treating myopia. This study evaluated PRK treatment of hyperopic anisometropic amblyopia using outcome measures of BCVA, UCVA, stereo, refractive stability, and safety over three years


Magrabi Hospital, Asseer


Prospective, FDA approved and monitored, interventional case study in non compliant children, ages 7-13, with hyperopic anisometropic amblyopia treated with unilateral, topical anesthesia PRK and followed for three years.


Ten children with mean preoperative SE of +4.73(SD 0.98)and mean postoperative SE of +0.95(p-value=0.0017).Five(71.4%) children and six (86%) children were within 1D and 2D, respectively, of the sound eye. Initial mean BCVA was 0.86improved to 0.54 (SD 0.40),4lines of improvement (p-value= 0.0025).Initial mean UCVA was 0.99 (SD 0.38) and improved to 0.56(SD 0.40) 5lines of improvement (p-value=0.0006) and were spectacle free.Uncorrected stereo acuity improved Postoperative, all were better than 400┬░arc (p-value=0.16).All patients tolerated the procedure well, 40% developed minimal, non-significant subepithelial haze, that disappeared by 12 months.Corneal topography revealed no corneal instability or changes


Discussion: Monocular and binocular function improved and remained stable after PRK in all patients without further amblyopia therapy. This substantiates prolonged plasticity and ability to have sustainable amblyopia improvement. Long term follow up of PRK resulted in no haze or corneal instability. Conclusion: PRK is safe and effective way of treating hyperopic anisometropic amblyopia in patients who fail traditional therapy.

Financial Disclosure:


Back to previous